ReviewBreast care (Basel, Switzerland)2020
Genomic Signatures in Luminal Breast Cancer.
Review in Breast care (Basel, Switzerland), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 33 citations in OpenAlex.
- Comparison of a Novel MRNA-Based Breast Cancer Subtyping Assay with PAM50 and Oncotype DX in Estrogen Receptor-Positive/HER2-Negative Breast Cancer: An Exploratory Age-Stratified Retrospective Cohort Study.Current issues in molecular biology · 2026Article
- De-escalating axillary surgery in early breast cancer: external validation of a retrospective cohort.Journal of cancer research and clinical oncology · 2026Observational
- Breast cancer pathogenesis, diagnosis and treatment: a comprehensive review.Frontiers in oncology · 2026Review
- Bibliometric Analysis of The Global Research Trends on The Application of Tamoxifen in The Treatment of Breast Cancer Over The Past 50 Years.The Malaysian journal of medical sciences : MJMS · 2025Review
- Integrated immune-related gene signature predicts clinical outcome for patients with Luminal B breast cancer.Gland surgery · 2024Article
- Article
- Identification of Patients with Early HR+ HER2- Breast Cancer at High Risk of Recurrence.Geburtshilfe und Frauenheilkunde · 2024Article
- Genomic signatures in breast cancer in a real-world setting: Experience in a Brazilian Northeastern Center.Breast disease · 2024Article
- Expression profiling of luminal B breast tumor in Indian women.Journal of cancer research and clinical oncology · 2023Article
- Development of a Machine Learning-Based Prognostic Model for Hormone Receptor-Positive Breast Cancer Using Nine-Gene Expression Signature.World journal of oncology · 2023Article
- Deregulated miRNA Expression in Triple-Negative Breast Cancer of Ancestral Genomic-Characterized Latina Patients.International journal of molecular sciences · 2023Article
- Article
- Advances in PET/CT Imaging for Breast Cancer.Journal of clinical medicine · 2023Review
- Article
- Potential Role of Circulating miRNAs for Breast Cancer Management in the Neoadjuvant Setting: A Road to Pave.Cancers · 2023Review
- Omics approaches to understanding the efficacy and safety of disease-modifying treatments in multiple sclerosis.Frontiers in genetics · 2023Review
- PREDICT underestimates survival of patients with HER2-positive early-stage breast cancer.NPJ breast cancer · 2022Article
- Article
- RecurIndex assay as an aid for adjuvant chemotherapy decisions in HR-positive HER2-negative breast cancer patients.Frontiers in oncology · 2022Article
- Oncotype DX Recurrence Score in premenopausal women.Therapeutic advances in medical oncology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBreast cancer is a very heterogeneous disease and luminal breast carcinomas represent the hormone receptor-positive tumors among all breast cancer subtypes. In this context, multigene signatures were developed to gain further prognostic and predictive information beyond clinical parameters and traditional immunohistochemical markers. SUMMARY: For early breast cancer patients these molecular tools can guide clinicians to decide on the extension of endocrine therapy to avoid over- and undertreatment by adjuvant chemotherapy. Beside the predictive and prognostic value, a few genomic tests are also able to provide intrinsic subtype classification. In this review, we compare the most frequently used and commercially available molecular tests (OncotypeDX®, MammaPrint®, Prosigna®, EndoPredict®, and Breast Cancer Index KEY MESSAGES: Multigene assays can help to de-escalate systemic therapy in early-stage breast cancer. Only the Oncotype DX® and MammaPrint®
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.